---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-037650"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:25:25.160645+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine: 2024 net loss $109.4M, bitopertin NDA on track H2 2025 via accelerated approval

## Summary
- Full-year 2024 net loss $109.4M vs $76.4M in 2023; R&D expenses rose to $96.7M.
- Cash $489.9M at year-end; plus $243.3M net from Jan 2025 offering, funds operations into 2028.
- Bitopertin: FDA path to accelerated approval for EPP; NDA submission planned H2 2025.
- DISC-0974: Phase 2 MF anemia trial initiated; initial data expected H2 2025.
- DISC-3405: Phase 2 in polycythemia vera expected H1 2025; Phase 1 showed proof-of-mechanism.

## SEC filing metadata
- accession: 0001193125-25-037650
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/0001193125-25-037650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/d916827d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-037650
- JSON: https://secwatch.observer/filing/0001193125-25-037650.json
- Plain text: https://secwatch.observer/filing/0001193125-25-037650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.